Clinical trial

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

NCT03636685

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Anlotinib combined with pemetrexed and carboplatin, phase I Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Anlotinib combined with paclitaxel and carboplatin, phase I Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Anlotinib combined with pemetrexed and carboplatin, phase II Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Anlotinib combined with paclitaxel and carboplatin, phase II Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2018-08-15

PhasePHASE1 / PHASE2

Conditions

NSCLCverified · MONDO: non-small cell lung carcinoma

Adenocarcinomaverified · MONDO: adenocarcinoma

Squamous Cell Carcinomaverified · MONDO: squamous cell carcinoma

Interventions

Anlotinib combined with pemetrexed and carboplatin, phase IDRUG

Anlotinib combined with paclitaxel and carboplatin, phase IDRUG

Anlotinib combined with pemetrexed and carboplatin, phase IIDRUG

Anlotinib combined with paclitaxel and carboplatin, phase IIDRUG

Sponsors & collaborators

Chinese Academy of Medical Scienceslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03636685 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.